The majority of sexually active women will acquire a human papillomavirus (HPV) infection in their lifetime, and an estimated 10% of these infections can develop into cervical cancer. Women in all Canadian jurisdictions have access to cervical cancer screening using the cytology-based Papanicolaou (Pap) test. While implementation of the Pap test during the last few decades in Canada has contributed to a significant reduction in cervical cancer incidence and mortality, low sensitivity is a known limitation of this test. The available evidence suggests that HPV testing may perform better than Pap cytology in cervical cancer screening. Several jurisdictions, therefore, are considering, planning or piloting HPV primary screening programs.
CADTH is undertaking an Optimal Use project to assess the clinical and cost-effectiveness, safety, and patient experiences of HPV testing for primary cervical cancer screening. Ethical and implementation issues, as well as potential impact on the environmental will also be addressed.
Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.
The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.
cancer, cervical intraepithelial neoplasia, dna probes, early detection of cancer, mass screening, papillomavirus infections, screening, triage, uterine cervical dysplasia, uterine cervical neoplasms, vaginal smears, gynecology/obstetrics, laboratory tests, HPV, HPV infection, HPV infections, HPV test, HPV testing, HPV tests, Human Papillomavirus DNA Tests, Human Papillomavirus testing, Human Papillomavirus tests, cervical cancer, cervical neoplasm, human papillomavirus test